我々は２つの論文を用いてA薬との差別化を実施した。特に日本においてカリスマ的存在であるB先生にこの論文の解説をしてもらい講演会でレクチャーしていただいた。B先生の影響力はとても大きく、A薬からC薬への切り替えに効果的であった。高齢者に対するデータが2013年米国で発表された。このレジメンは肺がんに対するD薬が、とても新しく効果的なため、非寛解期の患者に対しても効果を示した。このデータをプロモーションすることで肺がんのレジメンが切り替わるきっかけになった。
![[削除済みユーザ]](https://secure.gravatar.com/avatar/695023b4efd563721d13716b1457bc73.png?d=identicon&mode=crop&r=PG&s=42)
評価
52
翻訳 / 英語
- 2014/12/04 09:18:54に投稿されました
We conducted differentiation with A by using two theses. Notably, we asked Doctor B, who is a charismatic figure in Japan, to explain and give us a lecture. He was so influential, making switching from A to B effective. In 2013, data for the elderly was published in the U.S.
In this regimen, since D was very new and effective for the lung cancer, it indicated effectiveness for the patients in remission too. Promoting this data has triggered switching of regimen for lung cancer.
In this regimen, since D was very new and effective for the lung cancer, it indicated effectiveness for the patients in remission too. Promoting this data has triggered switching of regimen for lung cancer.
★★★★☆ 4.0/1
評価
52
翻訳 / 英語
- 2014/12/04 02:28:06に投稿されました
We differentiated medicine A by using two theses. We also had professor B, who has a charismatic presence, especially in Japan, to commentate on these theses and give us a lecture at a meeting. Professor B's influence was dramatic, and was effective in changing from medicine A to medicine C. Data regarding senior citizens was announced in the United States in 2013. This regimen showed that medicine D is effective toward patients in their irremissible stages of cancer, since it is very new and effective for lung cancer. The promotion of this data was the trigger to changing the regimen for lung cancer
★★★☆☆ 3.0/1
